Furoxan |
| Names |
| Preferred IUPAC name |
| Other names Furazan N-oxide; Furazan 2-oxide |
| Identifiers |
| | |
| | |
| ChemSpider | |
| MeSH | C528141 |
| | |
| | |
InChI=1S/C2H2N2O2/c5-4-2-1-3-6-4/h1-2H NKey: KCMCIQNPQUSQKQ-UHFFFAOYSA-N NInChI=1/C2H2N2O2/c5-4-2-1-3-6-4/h1-2H Key: KCMCIQNPQUSQKQ-UHFFFAOYAH |
| |
| Properties |
| | C2H2N2O2 |
| Molar mass | 86.050 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). Infobox references |
Furoxan (1,2,5-oxadiazole 2-oxide) is a heterocycle of the isoxazole family and an amine oxide derivative of furazan. It is a nitric oxide donor.[1] As such, furoxan and its derivatives, such as ipramidil, are being actively studied as potential new drugs and insensitive high density explosives (4,4’-dinitro-3,3’-diazenofuroxan).
Furoxanes can be formed by dimerization of nitrile oxides.
References
|
|---|
| Forms | |
|---|
| Targets | |
|---|
NO donors (prodrugs) | - NONOates (diazeniumdiolates): Diethylamine/NO (DEA/NO)
- Diethylenetriamine/NO (DETA/NO)
- GLO/NO
- JS-K
- Methylamine hexamethylene methylamine/NO (MAHMA/NO)
- PROLI/NO
- Spermine/NO (SPER/NO)
- V-PYRRO/NO
- Unsorted: Cimlanod
- FK-409
- FR144220
- FR146881
- N-Acetyl-N-acetoxy-4-chlorobenzenesulfonamide
|
|---|
Enzyme (inhibitors) | | NOS | | nNOS | |
|---|
| iNOS | - 1-Amino-2-hydroxyguanidine
- 2-Ethylaminoguanidine
- 2-Iminopiperidine
- 1400W
- AEITU
- Aminoguanidine (pimagedine)
- AMT
- AR-C 102222
- BYK-191023
- Canavanine
- Cindunistat (SD-6010)
- EITU
- IPTU
- MITU
- N5-(1-Iminoethyl)-L-ornithine (L-NIO)
- N6-(1-Iminoethyl)-L-lysine (L-NIL)
- Nω-Methyl-L-arginine (L-NMA)
- Ronopterin (VAS-203)
- TRIM
|
|---|
| eNOS | |
|---|
| Unsorted | |
|---|
|
|---|
| Arginase | |
|---|
| CAMK | |
|---|
|
|---|
| Others | - Precursors: L-Arginine
- Nω-Hydroxy-L-arginine (NOHA)
- Indirect/downstream NO modulators: ACE inhibitors/AT-II receptor antagonists (e.g., captopril, losartan)
- ETB receptor antagonists (e.g., bosentan)
- L-Type calcium channel blockers (e.g., dihydropyridines: nifedipine)
- Nebivolol (beta blocker)
- PDE5 inhibitors (e.g., sildenafil)
- non-selective PDE inhibitors (e.g., caffeine)
- PDE9 inhibitors (e.g., paraxanthine)
- cGMP preferring PDE inhibitors (e.g., sildenafil, paraxanthine, tadalafil)
- Statins (e.g., simvastatin)
|
|---|
See also: Receptor/signaling modulators |